Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

Recombinant Human DPPIV/CD26 Fc Chimera (Catalog # 11141-SE) is measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).

2 μg/lane of Recombinant Human DPPIV/CD26 Fc Chimera Protein (Catalog # 11141-SE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 116-131 kDa and 230-260 kDa, respectively.

• Reactivity: Hu
• Applications: Enzyme Activity
• Format: Carrier-Free

Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is >3000 pmol/min/μg, as measured under the described conditions.
• Source: Human embryonic kidney cell, HEK293-derived human DPPIV/CD26 protein
  

  Human CD26 (Asn29-Pro766) Accession # CAA43118.1	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• N-terminal Sequence: Asn29
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Enzyme Activity
• Theoretical MW: 112 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 116-131 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Assay Procedure:
  • Assay Buffer: 25 mM Tris, pH 8.0
  • Recombinant Human DPPIV/CD26 Fc Chimera (rhCD26/Fc) (Catalog # 11141-SE)
  • Substrate: H-Gly-Pro-AMC (Bachem, Catalog # I-1225), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax M5 by Molecular Devices) or equivalent
  1. Dilute rhCD26/Fc to 0.2 ng/μL in Assay Buffer.
  2. Dilute Substrate to 200 μM in Assay Buffer.
  3. Load into a black plate 50 μL of 0.2 ng/μL rhCD26/Fc, and start the reaction by adding 50 μL of 200 μM Substrate. For Substrate Blank combine 50 μL of Assay Buffer and 50 μL of 200 μM Substrate.
  4. Read at excitation and emission wavelengths of 380 nm and 460 nm, respectively, in kinetic mode for 5 minutes.
  5. Calculate specific activity:

  Specific Activity (pmol/min/µg) = (Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)) / (amount of enzyme (µg))

  *Adjusted for Substrate Blank
  **Derived using calibration standard 7-amino, 4-Methyl Coumarin (Sigma, Catalog # A9891)
  Per Well:
  • rhCD26/Fc: 0.010 μg
  • Substrate: 100 μM

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human DPPIV/CD26 Fc Chimera Protein, CF

• ADABP
• ADCP-2
• ADCP2DPP IV
• Adenosine deaminase complexing protein 2TP103
• CD26 antigen
• CD26
• CD26T-cell activation antigen CD26
• dipeptidyl peptidase 4
• Dipeptidyl peptidase IV
• dipeptidylpeptidase 4
• dipeptidyl-peptidase 4
• dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2)
• DPP4
• DPPIV
• EC 3.4.14.5

Background

Dipeptidyl peptidase 4 (DPPIV, also known as CD26) is an approximately 110 kDa serine exopeptidase that releases Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligo- and polypeptides. Mature human DPPIV consists of a 6 amino acid (aa) cytoplasmic tail, a 22 aa transmembrane segment, and a 738 aa extracellular domain (ECD) that contains the catalytic active site (1). DPPIV is expressed as a noncovalent homodimer on the surface of epithelial cells, endothelial cells, and activated lymphocytes, and it can be released by MMP mediated shedding (2). It regulates immune and endocrine function through the cleavage of multiple chemokines, growth factors, and peptide hormones (3,4). It cleaves a range of peptide hormones including Glucagon, Glucagon-like Peptides 1 and 2, GIP, GHRH, Procalcitonin, Neuropeptide Y, and Substance P (5). It is released from adipocytes and induces insulin resistance in adipocytes and skeletal muscle (6). DPPIV also cleaves many chemokines, resulting in altered chemotactic activity (7-10) or impacting chemokine blockade of HIV-1 cellular infectivity depending on the chemokine target (7,9,11). It cleaves human GM-CSF and IL-3 and reduces their ability to promote myeloid cell development (12). In addition to enzymatic cleavage functions, DPPIV interacts with adenosine deaminase on T cells and with caveolin-1 on antigen presenting cells (13), provides costimulatory proliferation and activation signals to both CD4+ and CD8+ T cells (13,14), and serves as a cell entry coreceptor for HIV and coronavirus MERS-CoV-2 (15,16). DPPIV inhibitors are approved for therapeutic treatment in type 2 diabetes (17) and are being explored for treatment of several additional conditions including autoimmune diseases (18).

1. Tanaka, T. et al. (1992) J. Immunol. 149:481.
2. Rohrborn, D. et al. (2014) FEBS Lett. 588:3870.
3. Klemann, C. et al. (2016) Clin. Exp. Immunol. 185:1.
4. Mortier, A. et al. (2016) J. Leukoc. Biol. 99:955.
5. Waumans, Y. et al. (2015) Front. Immunol. 6:387.
6. Lamers, D. et al. (2011) Diabetes 60:1917.
7. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
8. Proost, P. et al. (2001) Blood 98:3554.
9. Ohtsuki, T. et al. (1998) FEBS Lett. 431:236.
10. Barreira da Silva, R. et al. (2015) Nat. Immunol. 16:850.
11. Guan, E. et al. (2002) J. Biol. Chem. 277:32348.
12. Broxmeyer, H.E. et al. (2012) Nat. Med. 18:1786.
13. Ohnuma, K. et al. (2007) J. Biol. Chem. 282:10117.
14. Hatano, R. et al. (2013) Immunology 138:165.
15. Callebaut, C. et al. (1993) Science 262:2045.
16. Raj, V.S. et al. (2013) Nature 495:251.
17. Makrilakis, K. (2019) Int. J. Environ. Res. Public Health 16:2720.
18. Huang, J. et al. (2022) Front. Immunol. 13:830863.